Advertisement
Screener

AN2 Therapeutics, Inc. (ANTX) Lessee, Operating Lease, Liability, to be Paid, Year One

1.3 / 5 stars · 8/31 Roast Me

AN2 Therapeutics, Inc. Lessee, Operating Lease, Liability, to be Paid, Year One

AN2 Therapeutics, Inc. (ANTX) had Lessee, Operating Lease, Liability, to be Paid, Year One of $54.00 thousand as of 2022-12-31, per its 10-K filed 2023-03-29.

Discontinued › Notes › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths · last filed 2023-03-29

  • 2022-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $54.00K.
Period endLessee, Operating Lease, Liability, to be Paid, Year One
2022-12-31$54.00K
10-K · filed 2023-03-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
PepGen Inc. (PEPG)United States$0.186B-1.73
ALX ONCOLOGY HOLDINGS INC (ALXO)United States$0.187B-3.52
Organogenesis Holdings Inc. (ORGO)United States$0.182B-3.70
Fortress Biotech, Inc. (FBIO)United States$0.188B0.91
Zentalis Pharmaceuticals, Inc. (ZNTL)United States$0.196B-2.48
ORAMED PHARMACEUTICALS INC. (ORMP)$0.199B1.13
Tonix Pharmaceuticals Holding Corp. (TNXP)United States$0.166B-1.34
Minerva Neurosciences, Inc. (NERV)United States$0.165B-0.66
Nkarta, Inc. (NKTX)United States$0.205B-1.73
ADC Therapeutics SA (ADCT)$0.163B-1.39